BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.5//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20250101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260928
DTEND;VALUE=DATE:20261001
DTSTAMP:20260528T115319Z
CREATED:20260528T115319Z
LAST-MODIFIED:20260528T115319Z
UID:43639-1790553600-1790812799@www.pharmajournalist.com
SUMMARY:7th Genome Editing Therapeutics Summit
DESCRIPTION:The FDA has shown its’ hand. The Plausible Mechanism Framework and new NGS safety guidance signal one thing clearly: regulators want genome editing therapies to reach patients. Biopharma is also pushing back with a surge of novel genome editing assets deployed in the last 2 years\, targeting rare and prevalent diseases with scarce treatment options. \n \nBut intent and support alone won’t get these therapies to patients. Developmental\, manufacturing\, and regulatory challenges still stand between the lab and the patients waiting. \nThat’s why the 7th Genome Editing Therapeutics Summit is returning to Boston this September\, as the only industry-focused meeting dedicated to applying breakthrough genome editing tools directly to the therapeutic setting. \nJoin R&D\, preclinical\, translational\, regulatory\, and c-suite leaders to answer one question: how do we maximize the application of genome editing therapies to patients who need them most? \nDon’t miss out on insights from AbbVie\, Bristol Myers Squibb\, Intellia Therapeutics\, Beam Therapeutics\, Sanofi\, and many more on how genome editing can move from a promising therapy to an essential one for patients facing the most genetically complex diseases.   \nWhat’s New in 2026? \nIn 2026\, companies are doubling down on translating cutting-edge genome editing technologies into clinically viable therapies. With the FDA’s new mechanism pathway reshaping strategy\, the decisions made now will determine which assets reach patients. \nAt this year’s summit you will: \n\nDelve into extrahepatic delivery strategies to widen your technology across multiple disease indications\n\n\nLearn from clinical companies building robust IND packages to fast-track development\n\n\nEvaluate immunogenicity and off-targeting case studies to sharpen your therapy’s safety profile\n\nExplore the Brand-New Agenda to Discover: \n\n3 days of content to find the sessions your program needs most\n\n\n50:50 clinical & preclinical speakers to find genome editing talks relevant to your development stage\n\n\n80% Directors\, VPs & C-suite to benchmark your genome editing strategy against the right decision-makers\n\n\n64% in vivo & 36% ex vivo agenda to fit your route of delivery\n\n\n2 brand-new workshops\n\nView the full program here to see the 18+ speaker faculty and full session details: https://ter.li/sda9n7qy
URL:http://www.pharmajournalist.com/event/7th-genome-editing-therapeutics-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260929
DTEND;VALUE=DATE:20261002
DTSTAMP:20260427T150843Z
CREATED:20260423T154336Z
LAST-MODIFIED:20260427T150843Z
UID:43381-1790640000-1790899199@www.pharmajournalist.com
SUMMARY:10th IPF Summit
DESCRIPTION:10th Anniversary Edition of the IPF Summit – \nSeptember 29 – October 1\, 2026 | Boston\, MA \nFor a decade\, the IPF Summit has been the go-to\, discussion-led forum uniting stakeholders across the pulmonary fibrosis ecosystem. In its 10th anniversary year\, the stakes\, and the opportunity\, have never been higher. \nFollowing a wave of positive Phase III readouts from leading companies including Bristol Myers Squibb\, United Therapeutics\, and Boehringer Ingelheim\, the field has entered a new era of momentum. But with this progress comes increasing complexity. As standards of care evolve and more therapies emerge\, the question is no longer can we develop treatments\, but how to do so smarter\, faster\, and with meaningful differentiation. \nThe 10th IPF Summit is the only end-to-end\, industry-led meeting designed to tackle this challenge head-on. \nBringing together 150+ experts across discovery\, translational science\, and clinical development\, from organizations including Bristol Myers Squibb\, United Therapeutics\, Boehringer Ingelheim\, Pfizer\, Novartis\, AbbVie\, PureTech Health\, Insilico Medicine\, and many more\, the summit offers a uniquely integrated view of the scientific\, clinical\, and strategic decisions shaping the next decade of IPF innovation. \nAcross dedicated content tracks\, dive into emerging biology and novel targets to unlock new therapeutic avenues\, biomarker-driven and translational strategies to generate clearer signals earlier and next-generation clinical trial design and combination approaches to succeed in an increasingly competitive landscape \nNew for 2026 includes a dedicated ILD & PPF Focus Day\, designed to unpack the complexity of fibrotic lung diseases beyond IPF\, alongside an investor panel offering insight into building conviction and demonstrating differentiated value in an evolving funding environment.\nWith 8+ hours of networking in an intentionally intimate setting\, the summit is built for honest\, high-value discussions\, giving you direct access to the people shaping the future of pulmonary fibrosis drug development. \nWhether you’re advancing early discovery\, translating assets into the clinic\, or positioning therapies in a crowded market\, this is where the field aligns on what success now looks like\, and how to achieve it. \nFind out more about the 10th Anniversary Edition of the IPF Summit: https://ter.li/5ny4yhvk
URL:http://www.pharmajournalist.com/event/10th-ipf-summit/
LOCATION:Hotel Commonwealth\, 500 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260929
DTEND;VALUE=DATE:20261001
DTSTAMP:20260617T115135Z
CREATED:20260617T115135Z
LAST-MODIFIED:20260617T115135Z
UID:43766-1790640000-1790812799@www.pharmajournalist.com
SUMMARY:Designing the AI-Enabled Life Sciences Workforce Summit Europe
DESCRIPTION:AI is no longer a future concept in life sciences – it is actively reshaping how work gets done\, how decisions are made\, and how value is created. Yet most organisations are still navigating how to move from ambition to enterprise-wide execution. \nThe Designing the AI-Enabled Life Sciences Workforce Summit Europe is the only forum built specifically for senior HR leaders to tackle this challenge head-on. Bringing together CHROs and workforce transformation leaders from leading drug developers\, this is where strategy meets execution – and where organisations learn how to redesign work\, skills\, and operating models to deliver measurable business impact at scale. \nAt a time when life science organisations must drive productivity\, innovation\, and growth without increasing headcount\, this event provides the practical frameworks\, peer insights\, and proven strategies you need to move faster with confidence. \nThis is not a conference about AI trends – it is a working forum focused on how life sciences organisations are redesigning work\, workforce strategy\, and operating models in response to AI. \nAcross two highly interactive days\, you will learn directly from leaders who are actively transforming their organisations – moving beyond pilots to deliver enterprise-wide impact. Through a unique blend of case studies\, discussion\, and working sessions\, you will leave not only inspired but equipped with clear\, actionable next steps. \nFor more information and to register online\, please click here.
URL:http://www.pharmajournalist.com/event/designing-the-ai-enabled-life-sciences-workforce-summit-europe/
LOCATION:Essential by Dorint Basel City\, Schönaustrasse 10\, Switzerland\, Basel\, 4058\, Switzerland
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260929
DTEND;VALUE=DATE:20261002
DTSTAMP:20260619T123225Z
CREATED:20260619T123225Z
LAST-MODIFIED:20260619T123225Z
UID:43799-1790640000-1790899199@www.pharmajournalist.com
SUMMARY:5th mRNA Process Development & CMC Summit 2026
DESCRIPTION:The mRNA Process Development & CMC Summit returns for its 5th Anniversary\, bringing together the brightest minds in mRNA development\, manufacturing\, and CMC strategy. \nAs the field continues to evolve at pace\, this milestone edition is your opportunity to connect\, learn\, and stay ahead of the curve with the leaders shaping the future of mRNA therapeutics\, including senior decision-makers from GSK\, Eli Lilly\, Centivax\, Circurna\, Sanofi\, BioNTech and more! \nFrom scaling processes and strengthening analytical capabilities to navigating global expansion and clinical readiness\, this is where the industry’s most pressing CMC challenges are tackled head-on. \nFind out more: https://ter.li/peoi4f1e
URL:http://www.pharmajournalist.com/event/5th-mrna-process-development-cmc-summit-2026/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR